Neuroleptic Malignant Syndrome (NMS): What are the Genetic Factors?

S. Bamforth,J. Hall

DOI: https://doi.org/10.1177/070674378703200430

1987-05-01

Abstract:later the patient developed fever at 38.5°C while on haloperidol 30 mg/ day and diphenhydramine 75 mg/ day. He exhibited lead-pipe rigidity with severe diaphoresis, and the following day; the diagnosis of neuroleptic malignant syndrome was made with CPK above 6,000. His temperature raised at 39.6°C three days later with CPK of 7,250. The patient had to undergo intensive management for NMS (dantrolene) and later on for treatment of hemoglobinuria and massive pneumonia. Over the course of ten days, Mr. A. slowly recovered. We would like to emphasize the change in medication from procyclidine to diphenhydramine that occurred one week prior to the onset of hyperpyrexia. Slight agitation motivated this change of anticholinergic drugs. This change is most important as two other cases of NMS where diphenhydramine was used in combination with haloperidol have recently come to our attention. Although the pathogenesis ofthis disorder is still obscure, the dopamine blockade hypothesis remains the most accepted theory (2). It is possible that a short-lasting and low potency central anticholinergic substance such as diphenhydramine does not adequately counteract the dopamine blockade of haloperidol. Thus this change may lead to an imbalance between cholinergic and dopamine transmission (3) and induce the NMS in some cases. In our experience an appropriate control of EPS and especially rigidity could prevent the development of NMS in some patients.